Abstract
A successful structure-based design of a class of non-peptide small-molecule MDM2 inhibitors targeting the p53-MDM2 protein-protein interaction is reported. The most potent compound 1d binds to MDM2 protein with a Ki value of 86 nM and is 18 times more potent than a natural p53 peptide (residues 16-27). Compound 1d is potent in inhibition of cell growth in LNCaP prostate cancer cells with wild-type p53 and shows only a weak activity in PC-3 prostate cancer cells with a deleted p53. Importantly, 1d has a minimal toxicity to normal prostate epithelial cells. Our studies provide a convincing example that structure-based strategy can be employed to design highly potent, non-peptide, cell-permeable, small-molecule inhibitors to target protein-protein interaction, which remains a very challenging area in chemical biology and drug design.
MeSH terms
-
Biomimetic Materials / chemical synthesis
-
Biomimetic Materials / chemistry
-
Biomimetic Materials / metabolism
-
Biomimetic Materials / pharmacology
-
Crystallography, X-Ray
-
Drug Design*
-
Indole Alkaloids / chemical synthesis
-
Indole Alkaloids / chemistry*
-
Indole Alkaloids / pharmacology
-
Models, Molecular
-
Nuclear Proteins / antagonists & inhibitors*
-
Nuclear Proteins / chemistry
-
Nuclear Proteins / metabolism
-
Proto-Oncogene Proteins / antagonists & inhibitors*
-
Proto-Oncogene Proteins / chemistry
-
Proto-Oncogene Proteins / metabolism
-
Proto-Oncogene Proteins c-mdm2
-
Spiro Compounds / chemical synthesis
-
Spiro Compounds / chemistry*
-
Spiro Compounds / pharmacology
-
Structure-Activity Relationship
-
Tumor Suppressor Protein p53 / chemistry
-
Tumor Suppressor Protein p53 / metabolism
Substances
-
Indole Alkaloids
-
Nuclear Proteins
-
Proto-Oncogene Proteins
-
Spiro Compounds
-
Tumor Suppressor Protein p53
-
Proto-Oncogene Proteins c-mdm2